In May 2012, a number of us listened spellbound as Janet Woodcock of the FDA announced at a meeting at the Brookings Institution that the agency would “reboot” their entire approach to antibiotic development (J. Woodcock, presented at an Expert Workshop on Facilitating Antibacterial Drug
No takes yet. Share an insight, caveat, or question.
Shlaes et al. (2013) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: